Journal Article
. 2007 Sep; 147(6):400-11.
doi: 10.7326/0003-4819-147-6-200709180-00010.

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection

Lillian Sung 1 Paul C Nathan  Shabbir M H Alibhai  George A Tomlinson  Joseph Beyene  
Affiliations
  • PMID: 17876022
  •     47 citations

Abstract

Background: Benefits of prophylactic hematopoietic colony-stimulating factors (CSFs) in adults and children receiving cancer chemotherapy or undergoing stem-cell transplantation (SCT) are unclear.

Purpose: To determine whether prophylactic CSFs decrease mortality, infections, and febrile neutropenia more than does placebo or no therapy in patients with cancer and in patients undergoing SCT.

Data Sources: Electronic searches of Ovid MEDLINE and EMBASE from inception until April 2007 and of the Cochrane Central Register of Controlled Trials until the second quarter of 2006.

Study Selection: We selected 148 trials that were reported in any language that randomly assigned patients to CSFs or to either placebo or no therapy. Prophylactic CSFs were given concurrently with or after initiation of chemotherapy.

Data Extraction: Two reviewers independently extracted data onto standardized forms.

Data Synthesis: Short-term all-cause mortality appeared to be similar between the prophylactic CSF and the control groups (7.6% vs. 8.0%; relative risk, 0.95 [95% CI, 0.84 to 1.08]; absolute risk reduction, 0.4% [CI, -0.5% to 1.4%]). Risks for infection-related death with CSFs and placebo or no therapy were 3.1% and 3.8%, respectively (relative risk, 0.82 [CI, 0.66 to 1.02]; absolute risk reduction, 0.8% [CI, 0.0% to 1.5%]). Use of CSFs reduced the following more than did placebo or no therapy: documented infections (median rate, 38.9% vs. 43.1%; rate ratio, 0.85 [CI, 0.79 to 0.92]), microbiologically documented infections (median rate, 23.5% vs. 28.6%; rate ratio, 0.86 [CI, 0.77 to 0.96]), and episodes of febrile neutropenia (median rate, 25.3% vs. 44.2%; rate ratio, 0.71 [CI, 0.63 to 0.80]).

Limitations: Trial designs, including assessments of infections, and participants were heterogeneous. Estimates of mortality effects were imprecise.

Conclusions: Prophylactic CSFs may have little or no effect on mortality but do decrease rates of infection in patients receiving cancer chemotherapy or those undergoing SCT.

Canadian supportive care recommendations for the management of neutropenia in patients with cancer.
C T Kouroukis, S Chia, +4 authors, J Mikhael.
Curr Oncol, 2008 Mar 05; 15(1). PMID: 18317581    Free PMC article.
Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care.
Ruth Pettengell, Matti Aapro, +5 authors, Jan Walewski.
Clin Drug Investig, 2009 Jul 14; 29(8). PMID: 19591512
Review.
Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Heather M Arnold, Peggy S McKinnon, +6 authors, David J Ritchie.
Pharmacotherapy, 2009 Jul 30; 29(8). PMID: 19637944    Free PMC article.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
Marcie Tomblyn, Tom Chiller, +16 authors, Centers for Disease Control and Prevention.
Biol Blood Marrow Transplant, 2009 Sep 15; 15(10). PMID: 19747629    Free PMC article.
Highly Cited.
A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells.
Nieves Vélez de Mendizábal, Iván Martínez-Forero, +4 authors, Iñaki F Trocóniz.
Pharm Res, 2010 Jan 27; 27(3). PMID: 20101520
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Matti Aapro, Jeffrey Crawford, Didier Kamioner.
Support Care Cancer, 2010 Mar 02; 18(5). PMID: 20191292    Free PMC article.
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
Alexandre Chan, Wing Hang Fu, +3 authors, Raymond Ng.
Support Care Cancer, 2010 Mar 17; 19(4). PMID: 20232087
Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis.
T Vandenberg, J Younus, S Al-Khayyat.
Curr Oncol, 2010 Apr 21; 17(2). PMID: 20404969    Free PMC article.
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Cornelius F Waller, Miguel Bronchud, Stuart Mair, Rodeina Challand.
Ann Hematol, 2010 Apr 30; 89(9). PMID: 20428872    Free PMC article.
Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Nuttapong Ngamphaiboon, Tracey L O'Connor, +2 authors, Ellen B Kossoff.
Med Oncol, 2011 Aug 06; 29(3). PMID: 21818673
Food-borne bacteremic illnesses in febrile neutropenic children.
Anselm Chi-Wai Lee, Nellie Dawn Siao-Ping Ong.
Hematol Rep, 2011 Dec 21; 3(2). PMID: 22184532    Free PMC article.
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Tallal Younis, Daniel Rayson, Kara Thompson.
Support Care Cancer, 2012 Jan 19; 20(10). PMID: 22252548
Systematic Review.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Review.
SEOM clinical guidelines for myeloid growth factors.
José Muñoz Langa, Pere Gascón, Javier de Castro, SEOM (Spanish Society of Clinical Oncology).
Clin Transl Oncol, 2012 Jun 23; 14(7). PMID: 22721792
Effects of granulocyte-colony stimulating factor and the expression of its receptor on various malignant cells.
Hee Won Moon, Tae Young Kim, +4 authors, Dong Soon Lee.
Korean J Hematol, 2012 Oct 17; 47(3). PMID: 23071478    Free PMC article.
Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model.
Wanjing Ding, Hiroyuki Shimada, +6 authors, Lingtao Wu.
Blood, 2012 Dec 18; 121(6). PMID: 23243275    Free PMC article.
Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care.
Lillian Sung, Theo Zaoutis, +4 authors, Children's Oncology Group Cancer Control and Supportive Care Committee.
Pediatr Blood Cancer, 2012 Dec 21; 60(6). PMID: 23255159    Free PMC article.
Review.
Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis.
J Younus, T Vandenberg, M Jawaid, M A Jawaid.
Curr Oncol, 2013 Jan 10; 19(6). PMID: 23300360    Free PMC article.
Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
Lillian Sung, Richard Aplenc, +3 authors, Alan S Gamis.
Blood, 2013 Mar 09; 121(18). PMID: 23471307    Free PMC article.
Colony-stimulating factors for febrile neutropenia during cancer therapy.
Charles L Bennett, Benjamin Djulbegovic, LeAnn B Norris, James O Armitage.
N Engl J Med, 2013 Mar 22; 368(12). PMID: 23514290    Free PMC article.
Review.
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
Didier Kamioner, Stefan Fruehauf, +3 authors, Christian Berthou.
BMC Cancer, 2013 Nov 19; 13. PMID: 24237790    Free PMC article.
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.
Gisoo Barnes, Ashutosh Pathak, Lee Schwartzberg.
Cancer Med, 2014 Nov 21; 3(6). PMID: 25410813    Free PMC article.
Review.
Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy.
Hirotaka Konishi, Hitoshi Fujiwara, +6 authors, Eigo Otsuji.
Int J Clin Oncol, 2015 Jul 22; 21(1). PMID: 26194809
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.
C Michel Zwaan, Edward A Kolb, +20 authors, Gertjan J L Kaspers.
J Clin Oncol, 2015 Aug 26; 33(27). PMID: 26304895    Free PMC article.
Highly Cited. Review.
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Oleg Gladkov, Vladimir Moiseyenko, +4 authors, Noa Avisar.
Oncologist, 2015 Dec 17; 21(1). PMID: 26668251    Free PMC article.
Biosimilars in the management of neutropenia: focus on filgrastim.
Désirée Caselli, Simone Cesaro, Maurizio Aricò.
Biologics, 2016 Mar 05; 10. PMID: 26937170    Free PMC article.
Review.
Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.
Lin Li, Xiaotian Qi, +12 authors, Lingtao Wu.
EMBO Mol Med, 2016 Nov 04; 8(11). PMID: 27737899    Free PMC article.
M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation.
Prashanth K Kandalla, Sandrine Sarrazin, +6 authors, Michael H Sieweke.
J Exp Med, 2016 Nov 05; 213(11). PMID: 27811055    Free PMC article.
Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.
R T Maziarz, R Brazauskas, +24 authors, M L Riches.
Bone Marrow Transplant, 2016 Dec 20; 52(2). PMID: 27991895    Free PMC article.
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
S Jaramillo, A Benner, +30 authors, R F Schlenk.
Blood Cancer J, 2017 May 27; 7(5). PMID: 28548643    Free PMC article.
Impact of acute hematological toxicity on treatment interruptions during cranio-spinal irradiation in medulloblastoma: a tertiary care institute experience.
Narendra Kumar, Raviteja Miriyala, +4 authors, Ankita Gupta.
J Neurooncol, 2017 Jun 04; 134(2). PMID: 28577033
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.
Peter A Fasching, Lothar Häberle, +19 authors, Liewei Wang.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100455    Free PMC article.
Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.
Sibylle Schirm, Christoph Engel, +2 authors, Markus Scholz.
J Cancer Res Clin Oncol, 2017 Nov 06; 144(2). PMID: 29103159    Free PMC article.
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Isabel Puértolas, Alberto Frutos Pérez-Surio, +2 authors, María Del Tránsito Salvador.
Eur J Clin Pharmacol, 2017 Nov 21; 74(3). PMID: 29152672
Modulating host immune responses to fight invasive fungal infections.
James E Scriven, Mark W Tenforde, Stuart M Levitz, Joseph N Jarvis.
Curr Opin Microbiol, 2017 Nov 21; 40. PMID: 29154044    Free PMC article.
Review.
Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.
Hisham Abdel-Azim, Weili Sun, Lingtao Wu.
Pharmacol Ther, 2019 Aug 31; 204. PMID: 31470030    Free PMC article.
Review.
A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment.
Jennifer Gill, Vinay Prasad.
Res Pract Thromb Haemost, 2020 Jan 29; 4(1). PMID: 31989081    Free PMC article.
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Julia Bohlius, Christine Herbst, +2 authors, Andreas Engert.
Cochrane Database Syst Rev, 2008 Oct 10; (4). PMID: 18843642    Free PMC article.
Systematic Review.
Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials.
Grace Egan, Paula D Robinson, +9 authors, Lillian Sung.
Cancer Med, 2019 Jul 06; 8(10). PMID: 31274245    Free PMC article.
Systematic Review.
Fungal infections in children with haematologic malignancies and stem cell transplant recipients.
William R Otto, Abby M Green.
Br J Haematol, 2020 Mar 12; 189(4). PMID: 32159231    Free PMC article.
Review.
[Comparative study on the efficacy and safety between pegfilgrastim (PEG-rhG-CSF) and recombinant human granulocyte colony-stimulating factor in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation after hematological malignancy].
F Yang, X D Sun, +11 authors, M Jiang.
Zhonghua Xue Ye Xue Za Zhi, 2017 Nov 23; 38(10). PMID: 29166733    Free PMC article.
Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Nicole Skoetz, Julia Bohlius, +3 authors, Jörg-Janne Vehreschild.
Cochrane Database Syst Rev, 2015 Dec 22; (12). PMID: 26687844    Free PMC article.
Systematic Review.
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.
Derry K Mercer, Deborah A O'Neil.
Front Immunol, 2020 Oct 20; 11. PMID: 33072081    Free PMC article.
Review.
Predicting neutropenia risk in patients with cancer using electronic data.
Pamala A Pawloski, Avis J Thomas, +3 authors, Gary H Lyman.
J Am Med Inform Assoc, 2016 Sep 18; 24(e1). PMID: 27638907    Free PMC article.
Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF).
Aylin Yucel, Anne Skalicky, +3 authors, Mark Bensink.
J Patient Rep Outcomes, 2021 Jan 19; 5(1). PMID: 33459887    Free PMC article.
The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.
Qian Fei, Han-Bo Chen, +3 authors, Song-Wang Chen.
Medicine (Baltimore), 2021 Apr 10; 100(14). PMID: 33832134    Free PMC article.
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
Mark Clemons, Dean Fergusson, +18 authors, REThinking Clinical Trials (REaCT) investigators.
Breast, 2021 Apr 27; 58. PMID: 33901921    Free PMC article.